Title: Vitamins China Monthly Report – May 2026 Commentary
Company dynamics
- In late-April 2026, Zhejiang Medicine, Bluestar Adisseo, and Nengter Technology successively released their Q1 2026 reports.
- On 29 April, 2026, Kingdomway reported its Q1 2026 net profit declined 46.11% YoY.
- In Q1 2026, Tianxin Pharma recorded a slight increase in revenue but a significant decline in net profit.
- On 11 May, 2026, Lianhuan Pharma subsidiary wins approval for vitamin B injection.
Project progress
- In late April 2026, CAAS achieved efficient biosynthesis of 25-hydroxyvitamin D3.
- On 28 April, 2026, Brother Pharma's Vitamin B3, B5 and intermediates project (phase I) passed acceptance check.
- On 14 May, 2026, Tianyin Biotech's 200 t/a sodium ascorbyl phosphate and 200 t/a tanning agent project (phase) passed acceptance check.
- On 15 May, 2026, Hangzhou Medical College published a patent entitled "A vitamin A, vitamin D3, vitamin E composite microsphere and preparation method".
The USD/RMB exchange rate in this Report is USD1.00=CNY6.8562 on 6 May, 2026, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.
Please purchase to view
Buy Now
Add to cart
